All Activity

Bipartisan senators have introduced a bill to provide $30 million in funding annually to establish psychedelic-focused “centers for excellence” at U.S. Department of Veterans Affairs (VA) facilities, where veterans could receive novel treatment involving substances like psilocybin, MDMA and ibogaine. As Trump administration officials continue to promote the therapeutic potential of psychedelics, with plans in the works to expand access and research opportunities, Sens. Ruben Gallego (D-AZ) and David McCormick (R-PA) filed the “Innovative Therapies Centers of Excellence Act” this week to help realize that goal. A House companion version of the bill—sponsored by Congressional Psychedelics Advancing Therapies (PATH) Caucus co-chairs Reps. Lou Correa (D-CA) and Jack Bergman (R-MI)—was introduced last year, but it has not yet advanced in the chamber. The House and Senate measures are substantively identical, with minor formatting differences. “When I came back from Iraq, I saw my fellow Marines, like so many other veterans, struggle to get the help they needed,” Gallego said in a press release. “Our veterans sacrificed so much for this country. We owe it to them to explore every treatment that can help them heal, including therapeutic uses of psychedelics that may finally break through when others haven’t. I’m proud to lead this bill to help the VA study promising alternative therapies that can save lives.” The legislation, SB 4031, would require VA to designate at least five of its medical facilities as centers for excellence that would be charged with researching the therapeutic potential of psychedelics for conditions such as anxiety, depression, post-traumatic stress disorder (PTSD) and substance misuse. It also lists several psychedelics that the lawmakers want to see explored: MDMA, DMT, ibogaine, ketamine and psilocybin. The VA under secretary could expand that list, and they could also add medical conditions that could be studied. “Our veterans face disproportionately high rates of PTSD, depression, and substance use disorders due to combat exposure, trauma, and challenges that follow them home,” McCormick said. “Every day, 17 of them die by suicide. That must change.” “The Innovative Therapies Centers of Excellence Act will ensure the VA keeps pace with the private sector by expanding access to cutting-edge treatments, like MDMA-assisted therapy, promoting ongoing research on veteran health outcomes, and closing gaps in treatment services for our veterans who need it most,” he said. “We owe them nothing less than our very best.” There are a number of factors that VA would need to take into account as it selected the facilities that would host the centers of excellence, including regional distribution, partnerships with accredited medical schools, ability to recruit scientists “capable of ingenuity and creativity in medical research efforts,” data collection capabilities and more. The legislation would provide for $30 million in appropriations for VA annually to carry out the research. VA would need to submit a report with findings and recommendations to veterans-focused congressional committees within two years of enactment and each subsequent year. Among other things, the report would need to detail activities being carried out at the centers, key findings from the research projects and recommendations on ways to “improve the delivery of innovative therapies to veterans.” Melissa Lavasani, founder and CEO of the Psychedelic Medicine Coalition (PMC), said on Thursday that the bill “represents more than a research initiative” because it’s a “step toward building the clinical and policy infrastructure needed to responsibly integrate innovative therapies into modern healthcare.” “The VA can serve as a national proving ground, helping generate the evidence and care models that could ultimately benefit patients across the entire healthcare system,” she said. Amy Rising, a veteran and psychedelics reform advocate, said the veteran community “should never feel like the country they served has run out of options for their healing.” “We owe it to them to pursue every responsible, evidence-based pathway that could improve treatment for PTSD, depression, and other serious health conditions,” she said. While it’s uncertain if or when the House or new Senate bills might advance, their introduction this session represents a continuation of a unique theme in Congress over recent years, with bipartisan lawmakers increasingly finding common ground on psychedelics research and therapy. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Those lawmakers notably have allies in top positions within the Trump administration, including VA Secretary Doug Collins and U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. who have both embraced psychedelic policy reform. Kennedy recently told Joe Rogan on a podcast episode that the administration is “very anxious” to create a pathway for the novel therapies and that officials across federal agencies want to “get it out to the public as quickly as possible.” Multiple veterans groups also recently advised congressional lawmakers about the need to continue exploring psychedelics and marijuana as alternative treatment options for the military veteran population at hearings on Capitol Hill. The Wounded Warrior Project (WWP) and Veterans of Foreign Wars (VFW) specifically cited the Innovative Therapies Centers of Excellence Act as an example of a reform they’re backing. Correa and Bergman, the House sponsors of that legislation, separately filed a bill in January that would also promote research into the therapeutic potential of certain psychedelics in the treatment of serious mental health conditions experienced by veterans. The bipartisan duo in January also discussed the importance of strategically advancing psychedelics reform in a way that mitigates bureaucratic conflict and the influence of outside interests. Even just one misstep could threaten to upend the movement, they said. Last year, the VA secretary touted his role in promoting psychedelics access for veterans with serious mental health conditions, saying he “opened that door probably wider than most ever thought” was possible. The department in 2024 faced criticism after rejecting a grant application from an organization that helps connect veterans to programs abroad where they can receive psychedelic therapy to treat serious mental health conditions. Meanwhile, in November, Kennedy, Vice President JD Vance, the FDA commissioner and other Trump administration officials attended a “Make America Healthy Again” summit that featured a session dedicated to exploring psychedelic medicine. In June, Kennedy said his agency is “absolutely committed” to expanding research on the benefits of psychedelic therapy and, alongside of the head of FDA, is aiming to provide legal access to such substances for military veterans “within 12 months.” The secretary also said in April that he had a “wonderful experience” with LSD at 15 years old, which he took because he thought he’d be able to see dinosaurs, as portrayed in a comic book he was a fan of. Last October, Kennedy specifically criticized FDA under the prior administration over the agency’s “suppression of psychedelics” and a laundry list of other issues that he said amounted to a “war on public health” that would end under the Trump administration. Photo elements courtesy of carlosemmaskype and Apollo. The post Bipartisan Senate Bill Would Create Psychedelic-Focused VA Research Centers To Explore Innovative Treatments For Veterans appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

very nice content pls write more Dunearn House Frasers

“Cannabis consumers as a group do not have a political party preference that differs from the general electorate.” By Andrew Graham, NuggMD The persistent assumption that cannabis consumers are not sufficiently loyal to the Republican Party has always stood in the way of progress, to one degree or another, in the fight to end prohibition. With Republicans in unified control of the government and an executive order to complete the process of rescheduling the plant in force, that assumption affects how audiences who are not necessarily in tune with the culture think and act with respect to cannabis policy. Cannabis consumers are the main stakeholders in any change to the legality of the plant. Whether they favor or disfavor the people in power is an obvious factor in what happens next. That is why it’s worth zooming in fully on whether that persistent assumption is true, and if so, to what degree. As it turns out, the notion that cannabis consumers are predisposed as a group to vote a certain way is flat-out wrong. The data says cannabis consumers as a voting bloc have the same partisan composition as the general electorate. The bloc does not favor Democrats, “liberals” or progressives, nor does it disfavor the Republican Party. Here’s how we know: The NuggMD-Marijuana Moment Presidential Approval Poll has been monitoring the political affiliation of cannabis consumers since last spring. Our first set of consolidated data on political affiliation (combined n = 2,081), released today, shows no statistically significant difference between cannabis consumers and everybody else when it comes to political affiliation. In the 31 states that we poll in, cannabis consumers identify as Republican, Democrat or something else at the same rate as the general population of those states, as measured in the 2024 Cooperative Election Study, a benchmark survey on political affiliation that drills down to the state level. In other words, cannabis consumers as a group do not have a political party preference that differs from the general electorate. Cannabis consumers General population* Republican 26.5% 28.6% Democrat 35.7% 33.6% Other/Something else 37.8% 37.8% Cooperative Election Study 2024, n≈60,000, filtered to 31 states, weighted by commonweight. The differences shown fall within the pooled margin of error of ±2.15 percent and are not statistically significant. Notably, our polling footprint is already 1.5 percentage points more Democratic than the nation as a whole. Taking that handicap into account, the top-lines are essentially the same. Putting adult-use on state ballots may juice turnout, which generally benefits Democratic candidates. But the data shows the harmful results of prohibition are felt equally across partisan lines. We have also been polling the degree to which effectuating pro-cannabis policy, such as moving the plant to Schedule III, would cause the voting bloc in question to shift its level of support for the current administration. This is the area in which the cannabis consumer voting bloc is unique. Party identification is one of the most stable and slowest-moving psychological attachments a voter holds. Nevertheless, our consolidated data across three waves of presidential approval polls conducted during the past year shows a considerable political reward is available to President Donald Trump if Attorney General Pam Bondi obeys his order to complete the rescheduling process. That reward is extraordinarily durable. For instance, more than four in 10 respondents who disapprove of the administration say they would support it more for getting rescheduling done. This is not the same thing as switching party affiliation, but one can view it as a similar form of partisan defection. “If the Trump administration were to reschedule or legalize cannabis, would that change your level of support for it?” (n=1624) Much more A bit more Total movable No change Those who approve 52.0% 8.5% 60.6% 38.6% Those who are neutral 40.9% 10.1% 50.9% 48.5% Those who disapprove 28.7% 14.8% 43.6% 55.2% Forty-three million American adults consume cannabis with regularity, and it is a majority-Republican constituency in that more cannabis consumers live in states the president won in 2024 than in states he did not win. The takeaway is clear: Cannabis consumers aren’t going to fall for empty promises on rescheduling, but they will give credit for it where and when it’s due. Andrew Graham is head of communications for NuggMD. The post The Cannabis Consumer Community Is Just As Bipartisan As The General Population, Polling Data Shows (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

An Ohio campaign is making a final push for signatures to put a referendum on the November ballot that would repeal a law rolling back the state’s marijuana law and ban the sale of consumable hemp products outside of dispensaries. With about a week until a signature turn-in deadline, Ohioans for Cannabis Choice is calling on supporters to spread the word and ensure that they’re able to submit the requisite 248,092 signed petitions by March 19 to secure ballot placement. If the petition drive is successful, the implementation of the cannabis law enacted by Gov. Mike DeWine (R) after the state legalized adult-use marijuana would be put on hold until voters could have their say. If activists fall short, the controversial SB 56 would take effect immediately after the signature submission deadline. Dozens of Ohio businesses—including smoke shops, breweries and local retailers—are hosting petitions on site for voters to sign. Ohioans for Cannabis Choice has an interactive map showing those locations, and it’s urging supporters to promote that resource and urge others to join in the push to repeal SB 56. “This grassroots support is unprecedented in Ohio ballot initiatives and referendums, and we’re not done growing. But we are at a pivotal point in the campaign,” it said in an action alert last week, adding that the law that’d take effect without voter intervention would mean “the hemp products you are selling as businesses and purchasing as consumers, and supporting as Ohio voters WILL BE ILLEGAL and must immediately come off the shelves.” It's a beautiful day to sign the No On SB 56 petition! Find your signing location here -> https://t.co/MQO4YeUIjk pic.twitter.com/WGFytGlrMd — Ohioans for Cannabis Choice (@OH4cannabis) March 11, 2026 “Yes, like you, we are as mad as hell at this government overreach, this attack on consumers’ rights, and this potentially devastating blow to 6,000 small businesses and their employees,” it said. The governor, for his part, has been adamant about cracking down on the unregulated intoxicating hemp market—but the legislation he signed would do more than restrict the sale of cannabinoid products to dispensaries. It would also recriminalize certain marijuana activity that was legalized under the ballot initiative voters approved in 2023, and it’d additionally remove anti-discrimination protections for cannabis consumers that were enacted under that law. DeWine also used his line-item veto powers to cancel a section of the bill that would have delayed the implementation of the ban on hemp beverages. That action is being challenged in a lawsuit filed by breweries. Meanwhile, the referendum campaign working to block the law’s implementation has been in a time crunch since first floating the referendum late last year, only receiving approval to start collecting signatures for ballot placement last month after state officials initially rejected an earlier version of the petition that they said included factual errors. Making the ballot is only part of the battle, though. And while a majority of voters approved marijuana legalization—and polls have indicated that most residents are against aggressive restrictions on hemp sales—it remains to be seen whether the referendum would gain sufficient support in November to prevent an industry upheaval. The governor separately stirred controversy last month after telling critics of the law rolling back the state’s marijuana market and criminalizing intoxicating hemp products to stop “whining” and instead “be happy with their victory at the polls.” When the governor said that “proponents” of the referendum should take the win and accept the policy changes that are being implemented under SB 56, he wasn’t necessarily referring to the broader marijuana industry, as many stakeholders support reining in the consumable hemp market. DeWine’s office and a senator who led the charge to pass the bill have previously criticized the cannabis referendum campaign. A summary of the submitted referendum states that “Sections 1, 2, and 3 of Am. Sub. S. B. No. 56 enact new provisions and amend and repeal existing provisions of the Ohio Revised Code that relate to the regulation, criminalization, and taxation of cannabis products, such as the sale, use, possession, cultivation, license, classification, transport, and manufacture of marijuana and certain hemp products.” “If a majority of the voters vote to not approve Sections 1, 2, and 3 of the Act, then the enacted changes will not take effect and the prior version of the affected laws will remain in effect,” it says. Advocates have flagged a series of concerns with the law, pointing out, for example, that it would eliminate language in statute providing anti-discrimination protections for people who lawfully use cannabis. That includes protections meant to prevent adverse actions in the context of child custody rights, the ability to qualify for organ transplants and professional licensing. It would also recriminalize possessing marijuana from any source that isn’t a state-licensed dispensary in Ohio or from a legal homegrow. As such, people could be charged with a crime for carrying cannabis they bought at a legal retailer in neighboring Michigan. Additionally, it would ban smoking cannabis at outdoor public locations such as bar patios—and it would allow landlords to prohibit vaping marijuana at rented homes. Violating that latter policy, even if it involves vaping in a person’s own backyard at a rental home, would constitute a misdemeanor offense. The legislation would also replace what had been a proposed regulatory framework for intoxicating hemp that the House had approved with a broad prohibition on sales outside marijuana dispensaries following a recent federal move to recriminalize such products. Under the law, hemp items with more than 0.4 mg of total THC per container, or those containing synthetic cannabinoids, could no longer be sold outside of a licensed marijuana dispensary setting. That would align with a recently enacted federal hemp law included in an appropriations package signed by President Donald Trump. The federal law imposing a ban on most consumable hemp products has a one-year implementation window, however, and it appears the Ohio legislation would take effect sooner. As passed by the legislature, a temporary regulatory program for hemp beverages would have stayed in place in Ohio until December 31, 2026, but that provision was vetoed by the governor. The law also includes language stipulating that, if the federal government moves to legalize hemp with higher THC content, it’s the intent of the Ohio legislature to review that policy change and consider potential state-level reforms to regulate such products. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — In September, the Ohio Department of Cannabis Control (DCC) filed proposed rules to build upon the state’s marijuana legalization law, laying out plans to update regulations on labeling and packaging requirements. Ohio retailers sold more than $1 billion worth of legal marijuana products in 2025, according to data from the state Department of Commerce (DOC). Last March, a survey of 38 municipalities by the Ohio State University’s (OSU) Moritz College of Law found that local leaders were “unequivocally opposed” to earlier proposals that would have stripped the planned funding. Meanwhile in Ohio, adults as of June are able to buy more than double the amount of marijuana than they were under previous limits, with state officials determining that the market can sustainably supply both medical cannabis patients and adult consumers. Photo courtesy of Brendan Cleak. The post Ohio Campaign To Block Marijuana And Hemp Restrictions Faces Deadline For Ballot Referendum Signatures appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Online safety bill in Congress & marijuana biz; HI medical cannabis in healthcare facilities; Study: Marijuana a “gateway” to orgasm Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… By starting a $10 per month pledge on Patreon—or about 45 cents per issue of this newsletter—you can help us rely less on ads to cover our expenses, hire more journalists and bring you even more marijuana news. https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The Internal Revenue Service said a marijuana company’s argument that the 280E tax penalty doesn’t apply because cannabis doesn’t fall “within the meaning of” of a Schedule I drug would force the U.S. Tax Court to conduct its own rescheduling review under an “imaginary process” that is prohibited by federal law. The House Energy and Commerce Committee approved a bill that would require online platforms to take steps to prevent minors’ access to potentially sensitive content—including advertisements for cannabis products and certain other drugs and services. The Hawaii Senate passed a bill to allow terminally ill patients and qualifying patients over the age of 65 to use medical cannabis in health care facilities, subject to certain limitations. A new scientific review concludes that marijuana may be a “gateway to women’s orgasm” with significant therapeutic potential in the treatment of female orgasmic disorder/difficulty. “Five decades of convergent evidence…demonstrate a consistent association between cannabis use and enhanced orgasmic function.” Jordan Tishler of the Association of Cannabinoid Specialists argues in a new Marijuana Moment op-ed that a plan to launch cannabis kiosks in senior living communities presents access opportunities but also risks that need to be managed “within a medically supervised, ethically structured care model.” / FEDERAL Sen. Amy Klobuchar (D-MN) said at a hearing that “there’s a lot more we can do on hemp” and that it is “a growing market that we should be looking at, and not going backwards, on these opportunities to provide farmers with innovative sources of revenue amidst a difficult farm economy.” / STATES The Michigan Supreme Court heard arguments in a case on whether refraining from marijuana use can be mandated as a condition of probation. Oklahoma officials are being sued over a policy requiring medical cannabis businesses to have a certificate of occupancy. New York’s new top marijuana regulator discussed his goals for overseeing the legal industry. Massachusetts regulators are accepting public feedback on marijuana industry worker safety issues and a potential cannabis business license freeze. Oregon regulators published updated data on the psilocybin services program. The California Cannabis Advisory Committee will meet on Thursday. The Rhode Island Cannabis Control Commission will meet on Friday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL Colombian President Gustavo Petro criticized marijuana and drug prohibition in a speech before the Commission on Narcotic Drugs. / SCIENCE & HEALTH A review highlighted the “role of cannabis as a potential coping mechanism for caregivers of older adults experiencing emotional burden.” A study found that “cannabidiol mitigates secondary genital injury after thoracic trauma by regulating systemic inflammation and hormone receptor signaling.” / BUSINESS The Boston Garden Dispensary is being sued for allegedly violating the trademark of TD Garden. / CULTURE Harrison Ford dodged Jimmy Kimmel’s question about whether he has ever smoked marijuana with Woody Harrelson. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Max Jackson. The post IRS disputes cannabis company’s tax argument (Newsletter: March 12, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Excellent job curating trustworthy private servers with community-backed rankings. This is the definitive place to discover servers that value fairness and player activity. Real votes make all the difference when choosing where to play. Chicago Trolley

It's about time Instagram reconsiders its cannabis policy! WeedTube's petition is a crucial step. Many legal businesses are unfairly impacted. Imagine building a stunning structure in block blast , only to have it arbitrarily deleted – that's what these companies face. Let's hope Instagram levels the playing field and recognizes the growing legitimacy of the cannabis industry. Sign the petition!

Retro Bowl combines nostalgic graphics with engaging football management mechanics. Lead your team to legendary victories.

I am all that much satisfied with the substance you have specified. I needed to thank you for this extraordinary article. Retro Game Consoles

I like this post,And I figure that they having a great time to peruse this post,they might take a decent site to make an information,thanks for sharing it to me. Retro Game Handheld

The Hawaii Senate has passed a bill to allow qualifying patients to access medical marijuana at health facilities. After receiving a favorable report in committee last week, the legislation from Sen. Joy San Buenaventura (D) advanced through the full chamber in a unanimous 25-0 vote on Tuesday as part of the consent calendar. A House companion version of the proposal has also been moving through the process this session. The bill states that it’s the “intent of the legislature in enacting this chapter to support the ability of terminally ill patients and qualifying patients over sixty-five years of age with chronic diseases to safely use medical cannabis within specified health care facilities.” Advocates would have liked to see a mandate for health facilities to allow medical cannabis use, but as drafted it would simply permit such policies, while exempting residential treatment centers from the proposed law. Other exceptions built into the legislation, SB 2408, include provisions stipulating that medical marijuana couldn’t be used in substance misuse recovery hospitals, state hospitals or emergency departments of general acute hospitals “while the patient is receiving emergency services and care.” Smoking and vaping cannabis would remain prohibited in health facilities under the proposal, “provided that a home health agency shall only prohibit smoking or vaping immediately before or while home health agency staff are present in the residence.” General acute care hospitals couldn’t allow patients with a chronic disease to use medical cannabis unless they were terminally ill. In the event that a federal regulatory agency, Justice Department or Centers for Medicare and Medicaid Services (CMS) takes enforcement action against a health facility related to the medical cannabis policy, or if they explicitly notify the facility that they’re violating federal law, the health care institution could suspend the policy. Meanwhile, last week, another Hawaii Senate committee approved a bill to allow patients to immediately access medical cannabis once their registrations are submitted, instead of having to wait until their cards are delivered as is the case under current law. Buenaventura, chair of the Health and Human Services Committee, is also the sponsor of her chamber’s version of the proposal. Her panel more recently passed legislation to legalize low-dose and low-potency marijuana, even as members’ counterparts in the House of Representatives have said that cannabis prohibition will not be ended in the state this year. The legislation would allow adults 21 and older to legally possess and use certain amounts of low-dose and low-THC cannabis for personal use, with products limited to a maximum of 5 milligrams of THC per serving. In liquid form, they could have up to 5 milligrams of THC per twelve ounces. The Senate committee action comes after key House lawmakers signaled that cannabis legalization proposals would not be advancing in the 2026 session, citing a lack of sufficient support in their chamber. Despite renewed hopes that those bills—including one from House Judiciary and Hawaiian Affairs Committee Chairman David Tarnas (D) that would have put the issue of legalization before voters at the ballot—would advance this year, the sponsor and House Speaker Nadine Nakamura (D) said there wasn’t enough support within the legislature to pass them this round. State officials in January released a report on the potential economic impact of recreational marijuana legalization in the state, including revenue implications related to domestic and international tourism. All told, researchers said survey data and comparative analyses indicate that Hawaii could see anywhere from $46-$90 million in monthly marijuana sales by year five of implementation, after accounting for a maximum 15 percent tax rate on cannabis products. Hawaii’s Senate last year narrowly defeated a proposal that would have increased fivefold the amount of cannabis that a person could possess without risk of criminal charges. Had the measure become law, it would have increased the amount of cannabis decriminalized in Hawaii from the current 3 grams up to 15 grams. Possession of any amount of marijuana up to that 15-gram limit would have been classified as a civil violation, punishable by a fine of $130. A Senate bill that would have legalized marijuana for adults, meanwhile, ultimately stalled for the session. That measure, SB 1613, failed to make it out of committee by a legislative deadline. While advocates felt there was sufficient support for the legalization proposal in the Senate, it’s widely believed that House lawmakers would have ultimately scuttled the measure, as they did last February with a legalization companion bill, HB 1246. In 2024, a Senate-passed legalization bill also fizzled out in the House. Last year’s House vote to stall the bill came just days after approval from a pair of committees at a joint hearing. Ahead of that hearing, the panels received nearly 300 pages of testimony, including from state agencies, advocacy organizations and members of the public. Gov. Josh Green (D) signed separate legislation last year to allow medical marijuana caregivers to grow marijuana on behalf of up to five patients rather than the current one. And in July, the governor signed another bill that establishes a number of new rules around hemp products in Hawaii, including a requirement that distributors and retailers obtain a registration from the Department of Health. Lawmakers also sent a bill to the governor that would help speed the expungement process for people hoping to clear their records of past marijuana-related offenses—a proposal Green signed into law last April. That measure, HB 132, from Tarnas, is intended to expedite expungements happening through a pilot program signed into law in 2024 by Green. Specifically, it will remove a distinction between marijuana and other Schedule V drugs for the purposes of the expungement program. The bill’s proponents said the current wording of the law forces state officials to comb through thousands of criminal records manually in order to identify which are eligible for expungement under the pilot program. Meanwhile, in November, Hawaii officials finalized rules that will allow medical marijuana dispensaries to sell an expanded assortment of products for patients—including dry herb vaporizers, rolling papers and grinders—while revising the state code to clarify that cannabis oils and concentrates can be marketed for inhalation. The department also affirmed its support for federal marijuana rescheduling—a policy change that President Donald Trump ordered to be completed expeditiously but has yet to come to fruition. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Regulators are also launching a series of courses designed to educate physicians and other healthcare professionals about medical marijuana as the state’s cannabis program expands. The underlying medical marijuana expansion bill signed by the governor in late June, in addition to allowing more patients to more easily access cannabis, also contains a provision that advocates find problematic. Before lawmakers sent the legislation to Green, a conference committee revised the plan, inserting a provision to allow DOH to access medical marijuana patient records held by doctors for any reason whatsoever. Photo courtesy of Brian Shamblen. The post Hawaii Senate Passes Bill To Allow Medical Marijuana Use By Seriously Ill Patients In Health Facilities appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

While marijuana may soon be rescheduled under federal law, that doesn’t currently exempt state-legal cannabis businesses from an Internal Revenue Service (IRS) code known as 280E that bars them from taking federal tax deductions, the agency argues in a new filing with the U.S. Tax Court. In response to a petition to the court filed by the New Mexico marijuana business Ultra Health—which challenged the conventional interpretation of the IRS code, which applies to tax deduction claims connected to the sale of Schedule I and Schedule II drugs under the Controlled Substances Act (CSA)—IRS said the issue has already been soundly settled by Congress and various federal courts. Those courts “have consistently held that section 280E is constitutionally valid and have created a robust legal authority supporting its validity and applicability to sellers of marijuana,” it said. “Federal courts have addressed the applicability of section 280E in over 40 published orders or opinions. No resulting order or opinion include a ruling or holding that section 280E is unconstitutional or inapplicable to cannabis sellers.” Ultra Health’s novel argument in support of its alleged eligibility for tax deductions is based on the fact that 280E applies to businesses that sell controlled substances “within the meaning of” Schedule I and Schedule II drugs under the CSA. (Emphasis added.) In its opening brief filed last year, the petitioner said that means the tax court “must determine the ordinary meaning of ‘within the meaning of schedule I and schedule II,'” and that interpretation shouldn’t be based exclusively on whether cannabis is simply listed as Schedule I. “A list, by itself, has no ‘meaning.’ To speak of ‘the meaning’ of a list is to speak of the characteristics that define it,” Ultra Health argued. “The characteristics that define schedules I and II of the CSA are the three-part classification criteria” that largely concern abuse potential and currently accepted medical value. “If a substance does not meet the section 812(b)(1) criteria, it does not fall within the statutorily defined meaning of schedule I and thus cannot be placed on the schedule I list. And if a substance on the schedule I list is revealed not to meet the section 812(b)(1) criteria, the CSA provides for its removal from that list,” it said. To that end, the Drug Enforcement Administration (DEA) and U.S. Department of Health and Human Services (HHS) under the Biden administration completed a review finding that marijuana does not meet the CSA criteria for a Schedule I drug and should be moved to Schedule III, which would make 280E tax restrictions inapplicable. President Donald Trump in December separately signed an executive order directing the attorney general to finalize the process of reclassifying marijuana—but that hasn’t formally materialized yet. And in the interim, IRS told the tax court that it’s an improper venue to independently make a scheduling-related determination. “This would create a seismic rift between how substances are controlled and identified under the CSA and how they are applied under tax law, and plainly Congress did not intend to hide this elephant in the mousehole of the ‘within the meaning of’ verbiage,” IRS said in the reply brief, which was filed last week. “Petitioner’s statutory text argument is inconsistent with the text of section 280E, established precedent, and the statutory and administrative framework that Congress created under the CSA and section 280E.” The petition from Ultra Health, which was also supported by several cannabis trade associations that submitted amici briefs in the case, further maintained that marijuana is not “prohibited” by the CSA and that Congress “has divested itself of Commerce Clause [of the U.S. Constitution] power to regulate marijuana,” IRS said in its latest filing. But the agency pointed to statute stipulating that only the Drug Enforcement Administration (DEA) or U.S. Department of Health and Human Services (HHS) can initiate a drug scheduling review. And while it acknowledged that DEA is “currently considering rescheduling, it has not yet published a final rule reclassifying marijuana.” IRS said “marijuana remains a Schedule I controlled substance, and was so during the entire period at issue, July 1, 2017, through June 20, 2020″—a period when Ultra Health argues it should have been eligible to take federal tax deductions despite selling cannabis. “Since marijuana was a Schedule I controlled substance during that period, the Court must ‘apply the law in effect at the time it renders its decision,’ and apply section 280E in those periods.” “Petitioner’s interpretation ignores the operative fact that marijuana remains a Schedule I controlled substance pursuant to the CSA,” the filing states. “Petitioner’s request that the Court reschedule marijuana pursuant to an imaginary process which is prohibited by the clear procedures of the CSA must be denied.” IRS also emphasized that the CSA and 280E “are sister statutes, and must not be read to conflict, absent clear congressional intent.” “Petitioner’s argument thus runs afoul of black letter law on interpreting sister statutes harmoniously and presuming that similar terms operate and contain consistent meanings across statutes… Plainly, absent clear intent to the contrary, Congress did not intend for the CSA and section 280E to conflict,” it said. “Instead, the CSA and section 280E must be read in harmony and to avoid inconsistent outcomes; if a substance is currently identified as a Schedule I or II controlled substance under the CSA, then it is a substance ‘within the meaning’ of Schedule I or II for purposes of section 280E.” The petitioner’s interpretation “effectively bestows rescheduling authority for controlled substances to the Court and creates incongruity between section 280E and the CSA,” it continues. “Petitioner’s argument fails because it ignores this important context within the CSA and would implicitly repeal the administrative process and roles delineated in the CSA for rescheduling substances.” “Absent clear intent to the contrary, Congress did not intend for the CSA and section 280E to conflict by having conflicting avenues for rescheduling. Instead, the CSA and section 280E must be read in harmony to avoid such inconsistent outcomes and the implicit repeal of the procedures by which a provision might be rescheduled. This conflicting interpretation and inconsistent outcome are not supported by the legislative history of section 280E or case law. The Court does not have authority to undertake an independent evaluation of the CSA scheduling criteria to determine where a drug fits within the Schedules. Such a reading is inconsistent with the plain language of the statute and canons of statutory construction.” Putting a finer point on the issue, IRS said 280E “should not be interpreted in a way that leads to inconsistent results with the CSA and functionally circumvents its procedural requirements for scheduling.” As for the scientific review into marijuana conducted by HHS and the Food and Drug Administration (FDA) that led to a rescheduling recommendation under former President Joe Biden, Ultra Health’s argument that the agencies’ conclusion should factor into its eligibility under 280E is “irrelevant” because “DEA is ultimately responsible for rescheduling,” IRS said in the filing, which was noted earlier by Law360. “Moreover, even when rescheduling occurs, there is no authority for the proposition that it would be retroactive to the tax years at issue,” it said. “Marijuana was ‘within the meaning of schedule I and II’ during the tax years at issue and still is today.” Further, the petitioner’s claim that a congressional spending bill rider preventing DOJ from using its funds to interfere in state medical marijuana programs is “misplaced and confuses funding priorities with the conduct Congress has clearly prohibited,” IRS said. “Section 280E provides that no deduction is allowed for amounts paid in carrying on any trade or business if such business consists of trafficking in controlled substances which is prohibited by state or federal law.” “If medical marijuana is not ‘prohibited’ by the CSA because Congress limited DOJ’s funding in one year, it would retroactively become prohibited if, in a subsequent year, DOJ funding were to be reinstated. And this still cannot explain how this would apply in partial year funding scenarios, or if Congress were to again subsequently restrict DOJ enforcement funding. This miasma of a system is, of course, easily avoided by applying the CSA (and appropriation riders) as written, which is the only permissible approach to statutory construction; selling marijuana is prohibited by the text of the CSA, and the appropriations riders’ only impacts are, as their texts say, to limit funds being used for limited purposes during limited periods of time.” Put simply, “the CSA clearly prohibits the sale of marijuana, and section 280E has a clear and consistent meaning when read as a whole. Accordingly, the judicial inquiry is at an end,” it said. “Unless Congress or the DEA reschedule marijuana, or Congress amends section 280E, we must conclude that Congress intended to prohibit marijuana traffickers from taking deductions and credits.” “It follows that section 280E applies to petitioner to disallow deductions in the tax years at issue,” IRS said. The Congressional Research Service (CRS) has separately discussed prior attempts to challenge 28oE as it applies to state-legal marijuana businesses. In a report published last month, CRS pointed out that judges in the Tax Court issued a majority opinion upholding 280E and determining that the statute doesn’t violate the U.S. Constitution “because the disallowance of deductions does not constitute a ‘penalty’ for the purposes of the Eighth Amendment.” Meanwhile, IRS in 2024 warned the marijuana industry that some companies have, without a “reasonable basis,” filled out a supplementary form in an attempt to take federal tax deductions that they’re prohibited from receiving under a provision known as 280E. Of course, the federal tax issue may ultimately be resolved if the Justice Department follows through on Trump’s rescheduling directive, but despite a mandate to finalize the rule “in the most expeditious manner,” there haven’t been any updates on the status of that process in the weeks since the president signed the order. The post Marijuana Businesses Can’t Force Court To Do ‘Imaginary’ Rescheduling Review To Exempt Them From 280E Tax, IRS Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I'd personally declare that will this is the a terrific article of an wonderful man or woman, i am just very happy to discover this specific. 해외선물 개발

“Kiosk-based cannabis access for seniors can be a positive development only if it is embedded within a medically supervised, ethically structured care model.” By Jordan Tishler, Association of Cannabinoid Specialists A company recently declared its intention to roll out cannabis ordering kiosks in several senior-life communities in Arizona. The general idea is that residents would gain easier access to cannabis by being able to order products on the kiosk and have the product delivered right to them—kind of like online ordering but without needing a computer. But without appropriate safeguards for medical and non-medical users alike, the risk of this scheme may outweigh the benefit of greater access. The Association of Cannabinoid Specialists (ACS) strongly supports efforts to reduce access barriers for older adults who may benefit from cannabinoid-based therapies, especially those with limited transportation and mobility. A guided ordering interface that reinforces clinician-based treatment plans (aka prescriptions), clear product information and licensed dispensary sourcing is far preferable to unregulated or informal supply channels that some seniors might currently rely on. However, simply placing cannabis kiosks in independent living communities without robust clinical safeguards is not acceptable from a specialist perspective. Older adults typically have multiple comorbidities, complex polypharmacy and age-related changes in metabolism and cognition that substantially increase the risk of adverse events, drug–drug interactions and delirium. Furthermore, access to cannabis without clinical guidance leads to increased risk of misuse, dependence or addiction. Introducing a point-of-sale educational experience, even one described as “guided,” is not a substitute for individualized medical assessment, diagnosis and ongoing monitoring by clinicians trained in cannabinoid medicine. ACS welcomes the stated focus on education and clear product information at the point of ordering, including helping residents understand different product types, routes of administration and onset/duration profiles. But education delivered via kiosks or brand-affiliated educators remains inherently product- and transaction-centric, whereas proper cannabinoid care must be patient- and diagnosis-centric, integrated into the person’s full medical history, medication list and goals of care. For seniors, dose-finding, titration schedules, contraindications and deprescribing decisions cannot responsibly be handled through a consumer-facing digital interface. If cannabis kiosks are to be deployed in senior living communities, ACS believes the following elements are essential: Formal collaboration with the resident’s medical team, including communication of products, doses and changes over time, and documentation in the medical record. Access to qualified cannabinoid-trained clinicians (physicians, NPs) for pre-initiation assessment and ongoing follow-up, not just sales or brand educators. Clear protocols for referring both medical and non-medical users to, or back to, qualified clinicians for guidance and follow-up, particularly to screen for high-risk users and drug interactions, and to appropriately recommend and titrate regimens for older individuals. Transparent separation between clinical guidance and commercial interests, including clear disclosure of financial relationships and avoidance of quota-driven or upselling practices. Without these safeguards, the convenience and revenue opportunity described for dispensaries and communities risk outpacing appropriate clinical governance and patient safety protections. From ACS’s point of view, kiosk-based cannabis access for seniors can be a positive development only if it is embedded within a medically supervised, ethically structured care model. We encourage senior living operators, technology vendors and dispensaries to partner with cannabinoid medicine specialists to design programs where improved access and education are matched by rigorous clinical oversight, documentation and responsibility for outcomes. Jordan Tishler, MD is the president of the Association of Cannabinoid Specialists. The post Marijuana Ordering Kiosks For Seniors Present Both Opportunities And Risks (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

At Coastals 4x4, also known as the W.A. Diff Centre, we have over 120 years of combined experience working with 4×4’s and other vehicles. You get trustworthy advice and recommendations on how to improve your vehicle. Plus, we stock over 26,000 parts and all the best brands so you have everything under one roof.

A congressional committee has approved a bill aimed at protecting children online that could create complications for advertisers trying to promote legal marijuana and other regulated substances. Members of the House Energy and Commerce Committee last week passed the Kids Internet and Digital Safety (KIDS) Act, sponsored by Rep. Brett Guthrie (R-KY), the chair of the panel, in a 28-24 vote. This comes about three months after a similar proposal from Rep. Gus Bilirakis (R-FL) advanced through a subcommittee, while a Senate companion version awaits action. Under the latest legislation, online platforms would be prohibited from facilitating the “advertising of narcotic drugs, cannabis products, tobacco products, gambling, or alcohol to an individual that the covered platform knows is a minor.” The provision around drug use lists the “distribution, sale, or use of narcotic drugs, tobacco products, cannabis products, gambling, or alcohol” as risks that platforms would need to actively guard minors against. One section that was in prior iterations of the bill that seems to have been omitted from this latest version had stipulated that video streaming platforms would be required “to employ measures that safeguard against serving advertising for narcotic drugs, cannabis products, tobacco products, gambling, or alcohol directly to the account or profile of an individual that the service knows is a minor.” It’s unclear why that language was left out of the latest measure, H.R. 7757. Online platforms covered under the legislation include those that are publicly available for use, allow the creation of searchable usernames that can be followed, facilitate the “sharing and access to user-generated content,” is designed to promote engagement and uses user information to target advertising. Guthrie said in a press release that the measure’s passage represents one of the “meaningful steps forward to empower parents and protect children and teens online” the the panel has taken. “We owe it to parents. We owe it to communities. And most importantly, we owe it to the kids who are counting on us to get this right,” he said. Bilirakis said the bill is “designed to strengthen safeguards and increase transparency in the online space.” “I remain steadfast in my commitment to ensuring that children can safely navigate the digital world, while holding technology companies accountable for the platforms they operate,” he said. “Protecting our kids must always come before protecting corporate profits.” Few in the public policy space oppose the overall intent of the legislation, but some say its broad and potentially vague requirements could be difficult in practice. Shoshana Weismann, a fellow at the free-market R Street Institute, told Marijuana Moment last year when the Senate version was filed that the measure could ultimately block wide swaths of online advertising that are accessible by minors—even if the ads don’t target children, as the bill’s proponent’s suggest. “The problem is that the knowledge standard here is so loose,” she said, pointing to the bill’s definition of knowledge by platforms that they’re serving content to underage users. After last year’s Senate passage of the earlier measure—titled the “Kids Online Safety Act” (KOSA)—Jenna Leventoff, ACLU’s senior policy council and director of the civil right’s group’s national political advocacy division, said she was skeptical the legislation would pass constitutional muster. A number of states have attempted to adopt similar bills, Leventoff pointed out, and “in almost every case, a court has evaluated those laws and determined that they are likely to be unconstitutional.” “It’s extremely likely that KOSA is unconstitutional,” she said at the time,” and it makes me wonder why Congress is trying to enact something that won’t hold up in a court of law.” At the state level in 2024, Colorado’s Senate passed a bill similarly aimed at protecting minors from drug and other controversial content. But the proposal—which was later put on hold indefinitely by a House committee—drew fire from advocates such as Weismann at R Street Institute. She and other critics pointed out at the time that the bill could ban content around over-the-counter cough syrup and even, potentially, the Colorado governor’s social media posts in favor of the state’s legal psychedelics industry. Under existing regulations, states that have legalized have generally seen less cannabis consumption among young people compared to states where marijuana remains illegal, according to multiple studies. During a webinar in January, federal officials discussed the results of the latest Monitoring the Future (MTF) survey—which is supported by the National Institute on Drug Abuse (NIDA) and conducted every year for decades by the University of Michigan. Youth marijuana use is stable amid the state legalization movement, despite prohibitionist claims to the contrary, they said. And beyond that, more students are actually saying it’s harder to access cannabis and that they disapprove of occasional use. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — To reform advocates, the results of the survey reinforce the idea that creating a regulatory framework for cannabis where licensed retailers must check IDs and implement other security mechanisms to prevent unlawful diversion is a far more effective policy than prohibition, with illicit suppliers whose products may be untested and where age-gating isn’t a strictly enforced regulation. To that point, a separate federally funded study out of Canada that was released last year found that that youth marijuana use rates actually declined after the country legalized cannabis. The study was released about three months after German officials released a separate report on their country’s experience with legalizing marijuana nationwide. Back in July, federal health data also indicated that while past-year marijuana use in the U.S. overall has climbed in recent years, the rise has been “driven by increases…among adults 26 years or older.” As for younger Americans, rates of both past-year use and cannabis use disorder, by contrast, “remained stable among adolescents and young adults between 2021 and 2024.” Across the U.S., research suggests that marijuana use by young people has generally fallen in states that legalize the drug for adults. A report from the advocacy group Marijuana Policy Project (MPP), for example, found that youth marijuana use declined in 19 out of 21 states that legalized adult-use marijuana—with teen cannabis consumption down an average of 35 percent in the earliest states to legalize. The report cited data from a series of national and state-level youth surveys, including the annual MTF survey. Another survey from the U.S. Centers for Disease Control and Prevention (CDC) last year also showed a decline in the proportion of high-school students reporting past-month marijuana use over the past decade, as dozens of states moved to legalize cannabis. The post Congressional Lawmakers Approve Youth Safety Bill That Could Complicate Marijuana Businesses’ Online Outreach appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Connaught Place stands out for its energetic crowd and premium venues. In this setting, Connaught Place Escorts is frequently mentioned by those who appreciate organized companionship services that value privacy and friendly conversation.

Marijuana may be a “gateway,” but not in the stigmatized way it’s been portrayed by prohibitionists as a stepping stone to other drugs. Rather, a growing body of scientific literature signals cannabis is a “gateway to women’s orgasm” that could hold significant therapeutic potential in the treatment of female orgasmic disorder/difficulty (FOD), a new research paper says. For the analysis, published in the journal Current Sexual Health Reports last week, clinical sexologist Suzanne Mulvehill discussed how, even though FOD affects an estimated 72 percent of premenopausal women, there are currently no drugs approved by the Food and Drug Administration (FDA) to treat the condition. And cannabis represents a novel therapy that could fill that treatment gap. “Psychiatrists have traditionally been trained to define legitimate prescribing primarily through formally regulated pharmaceutical pathways, even while routinely prescribing medications off-label. For FOD, cannabis falls outside this conventional framework,” the report says. “Recognizing its therapeutic value therefore asks psychiatry to broaden its understanding of what constitutes medicine and evidence-based care, particularly for conditions that lack effective conventional pharmacologic options.” “Five decades of convergent evidence…demonstrate a consistent association between cannabis use and enhanced orgasmic function.” Mulvehill emphasized that incorporating cannabis into sexual medicine “will require openness to recognizing it as a therapeutic ally and developing clinical competence in its responsible use,” while rejecting antiquated framing that’s regarded marijuana as a “gateway” to dangerous drugs that must be “avoided at all costs.” “This stigma shaped society as a whole, as well as the training of psychiatrists and therapists,” Mulvehill, founder of the Female Orgasm Training Institute, said. “Yet cannabis today should be reframed: not as a gateway to illicit drug use, but as a gateway to women’s orgasm—and, more broadly, to restoring women’s sexual agency.” “Female Orgasmic Disorder/Difficulty remains one of the most prevalent yet least adequately treated conditions in women’s health,” the paper says. “The absence of FDA-approved pharmacological treatments, combined with the limited effectiveness of existing psychological and behavioral interventions, reflects a fundamental mismatch between the complexity of orgasmic difficulty and the scope of most current treatment models. The evidence reviewed demonstrates that cannabis occupies a uniquely promising position within this gap.” The analysis points to five decades of research into cannabis that’s demonstrated “consistent associations with improvements in orgasm frequency, ease, and satisfaction, while simultaneously reducing anxiety, inhibition, cognitive distraction, and bodily disconnection, which are core barriers to orgasmic function.” “Integrating cannabis into sexual medicine represents both a clinical and cultural shift,” the author wrote. “What distinguishes cannabis is not merely its ability to improve a single symptom, but its capacity to therapeutically influence multiple orgasm-facilitating and orgasm-inhibiting processes simultaneously, aligning with the multidimensional nature of Female Orgasmic Disorder/Difficulty.” “Moving forward will require an expansion of clinical perspective beyond traditional treatment frameworks, alongside interdisciplinary collaboration, provider education, and clear clinical guidance on dosing and administration to ensure safe, evidence-based care. Together, these developments position cannabis as a legitimate therapeutic ally in advancing equity, effectiveness, and innovation in women’s health care.” A previous scientific review Mulvehill coauthored last year pointed to ample evidence that cannabis is associated with improvements in symptoms of FOD. The research involved an analysis of one randomized controlled trial and 15 observational studies, using data from a total of 8,849 women. Based on the findings, study authors determined that marijuana “appears to be a promising treatment option for FOD/difficulty, with the majority of studies reviewed reporting improvements in orgasm function and satisfaction among women who use cannabis.” Relatedly, another study published last year determined that marijuana use is linked to increased sexual desire and arousal, as well as lower levels of sexual distress. In 2024, a study found that cannabis-infused vaginal suppositories seemed to reduce sexual pain in women after treatment for gynecological cancer. Combining the suppositories with online exercises in “mindful compassion” offered patients even more substantial benefits. “The outcomes favoured the [combined] group,” that research said “in which sexual function, levels of sexual arousal, lubrication, and orgasm increased, and the levels of sexual pain decreased.” Earlier research also found that administration of a broad-spectrum, high-CBD vaginal suppository was associated with “significantly reduced frequency and severity of menstrual-related symptoms” as well as the symptoms’ negative impacts on daily life. As for sexual fulfillment, a separate study last year found that while alcohol might be effective to “facilitate” sex, marijuana is better at enhancing sexual sensitivity and satisfaction. While alcohol increased some elements of sexual attraction—including making people feel more attractive, more extroverted and more desirous—people who used marijuana “have more sensitivity and they are more sexually satisfied than when they consume alcohol,” authors wrote. A broad scientific review of academic research on cannabis and human sexuality published in 2024 concluded that while the relationship between marijuana and sex is a complicated one, use of cannabis is generally associated with more frequent sexual activity as well as increased sexual desire and enjoyment. That article, published in the journal Psychopharmacology, also suggested that lower doses of marijuana may actually be best suited for sexual satisfaction, while higher doses could in fact lead to decreases in desire and performance. And it suggested effects may differ between men and women. Some advocates have cited the potential for cannabis to improve sexual function in women as a reason to add conditions such as FOD as a qualifying condition for medical marijuana. A 2020 study in the journal Sexual Medicine, meanwhile, found that women who used cannabis more often had better sex. Numerous online surveys have also reported positive associations between marijuana and sex. One study even found a connection between the passage of marijuana laws and increased sexual activity. Yet another study, however, cautions that more marijuana doesn’t necessarily mean better sex. A literature review published in 2019 found that cannabis’s impact on libido may depend on dosage, with lower amounts of THC correlating with the highest levels of arousal and satisfaction. Most studies showed that marijuana has a positive effect on women’s sexual function, the study found, but too much THC can actually backfire. Separately, a paper last year in the journal Nature Scientific Reports that purported to be the first scientific study to formally explore the effects of psychedelics on sexual functioning found that drugs such as psilocybin mushrooms and LSD could have beneficial effects on sexual functioning—even months after use. “On the surface, this type of research may seem ‘quirky,’” one of the authors of that study said, “but the psychological aspects of sexual function—including how we think about our own bodies, our attraction to our partners, and our ability to connect to people intimately—are all important to psychological wellbeing in sexually active adults.” Photo courtesy of Max Jackson. The post Marijuana May Be A ‘Gateway To Women’s Orgasm’ In Sexual Health Treatment, Scientific Analysis Finds appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Marijuana worker mortgage amendment; AZ cannabis smoke bill passes; CO medical marijuana in hospitals; Study: Psilocybin for quitting cigarettes Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Before you dig into today’s cannabis news, I wanted you to know you can keep this resource free and published daily by subscribing to Marijuana Moment on Patreon. We’re a small independent publication diving deep into the cannabis world and rely on readers like you to keep going. Join us at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Sen. Jeff Merkley (D-OR) filed an amendment to a housing bill on the Senate floor that would help marijuana industry workers qualify for federally backed mortgage loans by treating cannabis income the same as that derived from other industries. The Florida Supreme Court rejected a marijuana campaign’s request to review state officials’ rejection of tens of thousands of signatures for its legalization initiative, effectively killing the effort to get it on the 2026 ballot. Colorado lawmakers sent Gov. Jared Polis (D) a bill to allow terminally ill patients to use medical cannabis in healthcare facilities such as hospitals—but advocates say recent changes undermine the reform’s intent. The Arizona Senate passed a bill to punish people for creating “excessive” marijuana smoke or odor—including by making it punishable by up to four months in jail if it is “intentional or the person knowingly and substantially interferes with the comfortable enjoyment of life or property.” The Hawaii Senate passed a bill to create a psychedelics task force responsible for studying and making policy recommendations on providing access to breakthrough therapies such as psilocybin and MDMA. A new study published by the American Medical Association found that “a single psilocybin dose combined with manualized [cognitive behavioral therapy] yielded significantly greater smoking abstinence than the nicotine patch paired with the same CBT.” “Psilocybin is a promising candidate for smoking cessation that should move forward in the FDA process toward potential approval.” The National Cannabis Industry Association’s Adam Rosenberg and Dentons’s and Eric Berlin describe in a new op-ed how marijuana and hemp industry and advocacy groups have been meeting in an informal group called “The Commission” and are aligned on a “shared vision of more effective federal policy.” Ohio officials are facing a Friday deadline to respond to a lawsuit filed by breweries challenging Gov. Mike DeWine’s (R) veto of portions of a bill that would have allowed sales of hemp THC beverages until the end of the year. / FEDERAL The Drug Enforcement Administration Museum sent a newsletter highlighting the work of the agency’s Foreign-Deployed Advisory Support Team. / STATES Minnesota Gov. Tim Walz (D) signed a cannabis compact with the Lower Sioux Indian Community. Kansas Democratic gubernatorial candidate Cindy Holscher, currently a state senator, discussed her support for legalizing marijuana. The West Virginia House Health and Human Resources Committee advanced a bill to allow prescription of crystalline polymorph psilocybin following federal approval. The Rhode Island House Corporations Committee will consider several bills to amend cannabis laws on Thursday. Tennessee lawmakers discussed the benefits of legalizing marijuana. California regulators are asking a federal court to uphold the state’s cannabis business labor peace requirements. New York regulators took action against an unlicensed marijuana business. Massachusetts marijuana regulators submitted a budget request to lawmakers. Washington State regulators will host feedback sessions about cannabis rules this month. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL UK Prime Minister Keir Starmer responded to a lawmaker’s question about the cost of medical cannabis. / SCIENCE & HEALTH A review concluded that “cannabinoids represent a promising yet underexplored therapeutic option in rare and complex disorders.” A study found that patients “showed significant improvements in [post-treatment Lyme disease] symptom burden and quality of life from study enrollment through 1-month following the second dose of psilocybin (primary endpoint), with significant benefits sustained through 6 months.” / ADVOCACY, OPINION & ANALYSIS The Cannabis Financial Industry Group published a guide on how changes to federal hemp laws affect financial services providers. / BUSINESS Verano Holdings LLC is being sued for allegedly violating privacy laws by printing customers’ names and birthdays on receipts. SHF Holdings, Inc., d/b/a Safe Harbor Financial touted its moves to eliminate debt. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post Florida cannabis legalization measure blocked from 2026 ballot (Newsletter: March 11, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

This page is helpful for people searching for Escort Sector 43 online. The information about Sector 43 Escort Service is written in a professional way. The guide about Escorts Service in Sector 43 makes the process easy for new users.

Yes, I am entirely agreed with this article, and I just want say that this article is very helpful and enlightening. I also have some precious piece of concerned info !!!!!!Thanks. 해외선물 솔루션

The Hawaii Senate has approved a bill that would create a psychedelics task force responsible for studying and making policy recommendations on providing access to breakthrough therapies such as psilocybin and MDMA. After advancing through the committee process, the full Senate on Friday passed the legislation from Sen. Chris Lee (D) in a unanimous vote of 24-0, sending it to the House of Representatives for consideration. The measure would create a Mental Health Emerging Therapies Task Force that’d be tasked with spending two years reviewing the current scientific literature, supporting additional clinical research and “developing policy recommendations for safe, ethical, and culturally-informed implementation” of a psychedelics therapy program. “The legislature finds that addressing the mental health crisis affecting the residents of the State, particularly among veterans, first responders, and trauma survivors, is urgent,” the bill, SB 3199, states. “Suicide continues to be a leading cause of preventable death, and the State must explore all safe and effective treatment options supported by scientific evidence.” Noting that the federal Food and Drug Administration (FDA) has already designated psilocybin and MDMA as breakthrough therapies in the treatment of serious mental health conditions, which could lend to future rescheduling under the Controlled Substances Act (CSA), the Hawaii legislation says the state “must proactively prepare public health, clinical, and research systems for safe and equitable implementation.” Members of the task force would have to include representatives of the state Department of Health (DOH), the attorney general’s office, the Office of Wellness and Resilience (OWR), the University of Hawaii’s medical school and more. As drafted, DOH would have overseen the task force, but that was amended in committee to make it the responsibility of “an entity with demonstrated expertise in primary scientific research and pharmaceutical or medical education.” “Administrative placement of the task force within an entity with demonstrated expertise in primary scientific research and pharmaceutical or medical education shall not be construed to transfer, delegate, diminish, expand, or otherwise modify any regulatory, enforcement, licensing, scheduling, or rulemaking authority vested in the Department of Health, Board of Pharmacy, or any other state agency,” the bill as revised says. “All statutory authority relating to controlled substances, professional licensure, and public health regulation shall remain with the appropriate executive branch agencies as provided by law.” It appears that the bill would build upon prior work conducted by a separate psychedelics task force that convened for the first time in 2023, with a similar goal of exploring pathways for therapeutic access into FDA-approved breakthrough drugs like psilocybin. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, Hawaii senators recently approved a bill to legalize low-dose and low-potency marijuana, even as their counterparts in the House of Representatives say cannabis prohibition will not be ended in the state this year. A separate marijuana legalization bill that contained provisions making the reform contingent on changes to federal law or the state Constitution, SB 2421, was deferred for action. Both Senate and House panels additionally deferred action on a measure to allow for the sale of certain hemp-derived cannabinoid products. The Senate committee action comes after key House lawmakers signaled that cannabis legalization proposals would not be advancing in the 2026 session, citing a lack of sufficient support in their chamber. On Thursday, another Hawaii Senate committee separately passed legislation to allow patients to immediately access medical cannabis once their registrations are submitted, instead of having to wait until their cards are delivered as is the case under current law. Image courtesy of CostaPPR. The post Hawaii Senate Passes Bill To Create Psychedelics Task Force And Study Pathways To Access Psilocybin And MDMA appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Arizona Senate has passed a bill to penalize people who create “excessive” amounts of marijuana smoke or odor—a policy that’s received pushback from advocates who say the proposals amount to overreach that wasn’t envisioned under the state’s voter-approved legalization law. After being significantly dialed back in response to that criticism, the bill from Sen. J.D. Mesnard (R) advanced through the full chamber on Monday in a 20-9 vote. It now heads to the state House of Representatives for consideration. A separate companion resolution to put the issue before voters to decide failed, however, in a narrow 14-15 vote. Mesnard later made a successful motion to reconsider that defeat, however, so the measure could end up advancing upon a revote. As introduced, both measures would have added broad criminalization provisions back into the state’s cannabis use laws. But most of that punitive language was revised by the Senate Committee of the Whole. For example, it was changed to provide a clearer definition of “excessive” smoke and remove a reference to making the offense a “crime.” The bill as passed, however, would make it a public nuisance punishable by up to four months in jail and a $750 fine to create “excessive marijuana smoke or odor…if the person’s conduct is intentional or the person knowingly and substantially interferes with the comfortable enjoyment of life or property.” The latest revised definition of excessive cannabis smoke or odor describes it as “airborne emissions resulting from the burning, heating or vaporizing of marijuana or marijuana products,” according to a summary of the adopted amendment. Such emissions must also be “detectable by a reasonable person of ordinary sensibilities on other private property” and “occur for more than 30 consecutive minutes on a single occasion or on three or more separate days within a 30-day period.” The bill (SB 1725) that advanced through the full Senate and resolution (SCR 1048) that failed also now specify that “lawful possession or use of marijuana does not preclude a finding of nuisance, except that a court may consider possession of a valid registry identification card as a mitigating factor,” and they provide that “a person is not liable for committing a private nuisance unless the person has received notice of the interference and fails to abate it within five days.” Under the revised legislation, the affected party would first have to file a compliant with local officials before they pursue action with the state, but only if the municipality has already adopted an ordinance regulating excessive cannabis smoke or odor. A person would be deemed in violation of the law if a local court has issued a written order directing them to “abate excessive marijuana smoke or odor that constitutes a nuance” and that person “knowingly violates or refuses to comply with the order.” Each day of non-compliance after failing to adhere to the order would be consider a separate offense, and failure to comply would be a petty offense. “I wanted to clarify that we eliminated almost all of the criminal aspect of this. The only thing that remains is if you’re doing something intentional and substantial,” Mesnard said on Monday. “I’m not trying to interfere with somebody’s right to smoke. They can get high any number of other ways that this bill doesn’t implicate, but the moment that it does start to impact other people and their families, then it becomes an issue.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — In the background of this legislation, anti-cannabis activists are working to put an initiative on the state’s November ballot that would significantly roll back its voter-approved marijuana legalization law. A GOP congressional lawmaker said recently he’d like to see his state take that action—but he also acknowledged that President Donald Trump’s recent federal rescheduling order could complicate that prohibitionist push. Under the proposal, possession would remain lawful if voters chose to enact the initiative—and Arizona’s medical marijuana program would remain intact—but the commercial market for recreational cannabis that’s evolved since voters approved an adult-use legalization measure in 2020 would be quashed. A findings section on the latest initiative states that “the proliferation of marijuana establishments and recreational marijuana sales in this state have produced unintended consequences and negative effects relating to the public health, safety, and welfare of Arizonans, including increased marijuana use among children, environmental concerns, increased demands for water resources, public nuisances, market instability, and illicit market activities.” “Arizona’s legal marijuana sales have declined for two consecutive years, resulting in less tax revenue for this state, while some patients have relied on recreational use of marijuana instead of utilizing the benefits of this state’s medical marijuana program,” it says. The initiative would also instruct the legislature to make conforming changes by amending existing statute as it relates to the commercial industry, including tax and advertising rules. In order to make the ballot, the campaign will need to collect 255,949 valid signatures by July 2. If the proposal goes to voters and is approved, it would take effect in January 2028. It remains to be seen if there will be an appetite for repeal among voters, as 60 percent of the electorate approved legalization at the ballot in 2020. What’s more a poll from last year found majority support for medical cannabis legalization (86 percent), adult-use legalization (69 percent) and banking reform (78 percent). Meanwhile, senior residents in Arizona independent living communities could soon see a different kind of care service available in their neighborhoods: Kiosks allowing them to view and buy marijuana products from licensed dispensaries. The retailer Life Is Chill and cannabis technology company LoveBud announced last week that they were partnering for the launch of the novel initiative, which will involve deploying the kiosks in participating senior living communities that residents can use to learn about and order marijuana products for delivery. Photo courtesy of Martin Alonso. The post Arizona Senate Passes Bill To Punish People Over ‘Excessive’ Marijuana Odor Or Smoke appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Just one dose of psilocybin combined with therapy is associated with “significantly increased long-term abstinence” from cigarettes compared to nicotine patches, according to a new study published by the American Medical Association (AMA) that indicates the psychedelic “holds potential in the treatment of tobacco use disorder.” Researchers at Johns Hopkins University School of Medicine and the University of Alabama at Birmingham conducted the study, published in JAMA Substance Use and Addiction, finding more evidence about the therapeutic potential of single-dose psilocybin in tandem with cognitive behavioral therapy (CBT). The randomized clinical trial of cigarette smokers involved administering one high dose (30mg/70kg) of psilocybin or 8-10 weeks of Food and Drug Administration- (FDA) approved nicotine patch treatment, with both groups participating in a 13-week CBT program for smoking cessation. “A single psilocybin dose combined with manualized CBT yielded significantly greater smoking abstinence than the nicotine patch paired with the same CBT.” “A total of 82 psychiatrically healthy adult smokers participated in the study, with 68 (82.9 percent) completing the 6-month follow-up,” the paper says. “At 6-month follow-up, 17 participants receiving psilocybin (40.5 percent) exhibited biochemically verified prolonged abstinence compared with 4 participants using the nicotine patch (10.0 percent), and 22 participants receiving psilocybin (52.4 percent) exhibited biochemically verified 7-day point prevalence abstinence compared with 10 participants using the nicotine patch (25.0 percent).” Put another way, smokers who received psilocybin had more than six times greater odds of prolonged abstinence and more than three times greater odds of seven-day abstinence compared to the nicotine patch participants. “In this pilot randomized clinical trial, one dose of psilocybin with manualized CBT significantly increased long-term abstinence compared with nicotine patch treatment with CBT,” the authors said. “Psilocybin abstinence rates were higher than typical treatments, suggesting promise for tobacco smoking cessation.” “Participants in the psilocybin group smoked a mean of approximately 50 percent fewer [cigarettes per day] between the target quit date and 6-month follow-up,” they said. “The results of this study add to the increasing evidence that psychedelic treatment may have general anti-addiction efficacy across various addictive drugs.” “Psilocybin’s lack of direct interaction with nicotinic acetylcholine receptors (or receptors mediating the effects of other addictive drugs) highlights psychedelic therapy as a unique approach wherein the pharmacotherapy does not directly alter drug reinforcement or withdrawal but may instead act via higher-order psychological systems, such as changes in self-concept40 and enhanced psychological flexibility. Such mechanisms may also account for transdiagnostic benefits of psychedelic therapies (eg, for depression and anxiety). These psychological changes are likely associated with corresponding biological processes, just as there are presumably biological changes associated with successful psychotherapy. However, these biological processes are probably of a different nature and more difficult to characterize than those of traditional pharmacotherapies.” The study authors also said that the results of the psilocybin-assisted therapy clinical trial makes the psychedelic a “promising candidate for smoking cessation that should move forward in the FDA process toward potential approval.” As psychedelics policy reform advances in state legislatures across the U.S. and in Congress, Americans have shown growing interest in exploring the therapeutic potential of substances like psilocybin. To that point, a RAND Corporation analysis recently found that nearly 10 million American adults microdosed psychedelic drugs such as psilocybin, LSD or MDMA in 2025. A scientific review published by AMA last year that use of psilocybin has “surged” in the U.S. in recent years amid the decriminalization movement and in light of “promising clinical trial results” on its therapeutic potential. But the paper also pointed out that current federal laws present “a major barrier” to researchers gaining a better understanding of the psychedelic substance’s true impacts. Meanwhile, another study from last year found that psilocybin-assisted psychotherapy “showed significant reductions in alcohol consumption and high smoking cessation rates” and has potential to lessen opioid dependence. In 2024, meanwhile, two other studies—including one with contributions from a top federal drug official—examined psychedelics and alcohol use disorder (AUD). One found that a single dose of psilocybin “was safe and effective in reducing alcohol consumption in AUD patients,” while the other concludes that classic psychedelics like psilocybin and LSD “have demonstrated potential for treating drug addiction, especially AUD.” The National Institutes of Health that year also announced that it would put $2.4 million toward funding studies on the use of psychedelics to treat methamphetamine use disorders—funding that came as federal health officials noted sharp increases in deaths from methamphetamine and other psychostimulants in recent years, with fatal overdoses involving the substances rising nearly fivefold between 2015 and 2022. In 2023, the National Institute on Drug Abuse (NIDA) announced a $1.5 million funding round to further study psychedelics and addiction. Other research has also suggested that psychedelics could unlock promising new pathways to treat addiction. A first-of-its-kind analysis in 2023 offered novel insights into exactly how psychedelic-assisted therapy works for people with alcohol use disorder. In 2024, the National Center for Complementary and Integrative Health (NCCIH), which is part of the National Institutes of Health (NIH), identified the treatment of alcohol use disorder as one of a number of possible benefits of psilocybin, despite the substance remaining a Schedule I controlled substance under U.S. law. The agency highlighted a 2022 study that “suggested that psilocybin may be helpful for alcohol use disorder.” The research found people who were in psilocybin-assisted therapy had fewer heavy-drinking days over 32 weeks than the control group, which NCCIH said “suggests that psilocybin may be helpful for alcohol use disorder.” The post Psilocybin Helps People Quit Cigarettes More Effectively Than Nicotine Patches Do, American Medical Association-Published Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Colorado House of Representatives has sent a bill to the governor that would allow terminally ill patients to use medical marijuana in healthcare facilities such as hospitals—with recently added provisions that advocates argue undermine the measure’s original intent. Weeks after advancing through the Senate, with amendments, the legislation from Sen. Kyle Mullica (D) cleared the full House on third reading in a 49-12 vote on Tuesday. It now heads to the desk of Gov. Jared Polis (D), who has long championed cannabis reform in the state. “This is a good bill,” Rep. Ryan Gonzalez (R) said on the floor. “I think we should be able to give patients who are terminally ill, and other conditions, an option to have alternative methods of treatment. And that includes cannabis.” “I just can’t stress enough the importance of this bill for my district, for my community and for the people that I represent,” he said. “I went back to my district, and they were very excited about this—for people who have an opportunity to do this.” That said, advocates have been critical about changes made throughout the legislative process, arguing, for example, that making it so hospitals would have the option—rather than a mandate—to allow medical cannabis use in their facilities fundamentally undermines the intent of the reform. Jim Bartell, the father of a young California patient who passed away and who inspired the policy that’s become known as Ryan’s Law in his home state and several others, urged members of a House committee earlier this month to go back to original language of the bill and “use the original language of ‘shall’ and ‘must’” so that it doesn’t create a patchwork network of health facilities that permit or prohibit medical cannabis use. “For families like mine, this legislation is not theoretical. It’s part of ethical and compassionate care,” he said. Lieder, one of the bill sponsors, said in response to committee testimony that she had just learned about the amendments that advocates are opposing. That point was echoed during second reading on the House floor on Monday, but the measure was not ultimately revised accordingly. Under SB 26-007, health facilities would be permitted to develop guidelines for the use, storage and administration of medical marijuana. The Colorado Department of Public Health and Environment (CDPHE) would be prohibited from requiring compliance with the policy as a condition of obtaining or renewing a license or certification under the bill. Health facilities would be allowed to suspend the policy change if they risked enforcement action by a federal agency. “In FY 2026-27, workload in the Health Facilities and Emergency Medical Services Division in CDPHE will minimally increase to conduct outreach and education to licensed health care facilities regarding medical marijuana use,” a fiscal impact analysis says. “The department may also require legal services, provided by the Department of Law, related to rulemaking and implementation. This workload can be accomplished within existing appropriations.” Other amendments adopted in the Senate add additional compliance language, clarify that health facilities wouldn’t be required to store or dispense medical cannabis and limit legal liability for health institutions that permit medical marijuana use. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Colorado, the state saw over $1 billion in marijuana sales—a milestone the governor touted in December. The governor also said last month that his state should not have joined a lawsuit supporting the federal ban on gun ownership by people who use marijuana that recently went before the U.S. Supreme Court—and he personally opposes the state attorney general’s “legal position on this.” Photo courtesy of Mike Latimer. The post Colorado Bill To Allow Medical Marijuana Use In Hospitals Heads To Governor’s Desk appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net